Zhanxiong Luo

Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial

Yunpeng Yang, Song Qu, Jingao Li et al. · The Lancet Oncology · 2021 · 449 citations

Medicine, Oncology, Pharmacology +12

Administration of nimotuzumab combined with cisplatin plus 5-fluorouracil as induction therapy improves treatment response and tolerance in patients with locally advanced nasopharyngeal carcinoma receiving concurrent radiochemotherapy: a multicenter randomized controlled study

Ying Lu, Dagui Chen, Jinhui Liang et al. · BMC Cancer · 2019 · 30 citations · Full text

Medicine, Oncology, Pharmacology +15

LINC00511/hsa-miR-573 axis-mediated high expression of Gasdermin C associates with dismal prognosis and tumor immune infiltration of breast cancer

Kai Sun, Rixin Chen, Jingzhang Li et al. · Scientific Reports · 2022 · 27 citations · Full text

Medicine, Cancer Biology, Oncology +17

The Ratio of CD86+/CD163+ Macrophages Predicts Postoperative Recurrence in Stage II-III Colorectal Cancer

Guozeng Xu, Lei Jiang, Ye Cheng et al. · Frontiers in Immunology · 2021 · 16 citations · Full text

Medicine, Immunology, Oncology +17

Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial

Chuanhua Zhao, Yanqiao Zhang, Gang Wang et al. · Signal Transduction and Targeted Therapy · 2025 · 14 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17